Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. by Schiffmann, Raphael et al.
UCSF
UC San Francisco Previously Published Works
Title
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular 
events before enzyme replacement therapy.
Permalink
https://escholarship.org/uc/item/6rw2r1qx
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association, 24(7)
ISSN
0931-0509
Authors
Schiffmann, Raphael
Warnock, David G
Banikazemi, Maryam
et al.
Publication Date
2009-07-01
DOI
10.1093/ndt/gfp031
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Nephrol Dial Transplant (2009) 24: 2102–2111
doi: 10.1093/ndt/gfp031
Advance Access publication 13 February 2009
Fabry disease: progression of nephropathy, and prevalence of cardiac
and cerebrovascular events before enzyme replacement therapy
Raphael Schiffmann1,∗, David G. Warnock2, Maryam Banikazemi3,∗∗, Jan Bultas4, Gabor E. Linthorst5,
Seymour Packman6, Sven Asger Sorensen7, William R. Wilcox8 and Robert J. Desnick9
1Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke National Institutes of
Health, Bethesda, MD, 2Division of Nephrology, University of Alabama at Birmingham, Birmingham, AL, 3Department of Genetics
and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA, 4Department of Pharmacology, 3rd Faculty of
Medicine, Charles University Hospital, Prague, Czech Republic, 5Department of Endocrinology and Metabolism, Academic Medical
Center, University of Amsterdam, Amsterdam, the Netherlands, 6Division of Medical Genetics, Department of Pediatrics, University
of California, San Francisco, CA, USA, 7Section of Neurogenetics, Department of Medical Biochemistry and Genetics, University of
Copenhagen, Copenhagen, Denmark, 8Department of Pediatrics, Cedars-Sinai Medical Center, and Medical Genetics Institute,
UCLA School of Medicine, Los Angeles, CA and 9Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine,
New York, NY, USA
Correspondence and offprint requests to: Robert J. Desnick; E-mail: robert.desnick@mssm.edu
∗Current address: Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX, USA
∗∗Current address: Department of Pediatrics, Columbia University School of Medicine, New York, NY, USA
Abstract
Background. In Fabry disease, progressive glycolipid ac-
cumulation leads to organ damage and early demise, but
the incidence of renal, cardiac and cerebrovascular events
has not been well characterized.
Methods. We conducted a retrospective chart review of
279 affected males and 168 females from 27 sites (USA,
Canada, Europe). The pre-defined study endpoints included
progression of renal, cardiac and cerebrovascular involve-
ment and/or death before the initiation of enzyme replace-
ment therapy.
Results. The mean rate of estimated glomerular filtration
rate (eGFR) decline for patients was −2.93 for males, and
−1.02 ml/min/1.73 m2/year for females. Prevalence and
severity of proteinuria, baseline eGFR<60ml/min/1.73m2
and hypertension were associated with more rapid loss
of eGFR. Advanced Fabry nephropathy was more preva-
lent and occurred earlier among males than females. Car-
diac events (mainly arrhythmias), strokes and transient
ischaemic attacks occurred in 49, 11, 6% of males, and in
35, 8, 4% of females, respectively. The mean age at death
for 20 male patients was 49.9 years.
Conclusions.Baseline proteinuria, reduced baseline eGFR,
hypertension and male gender were associated with more
rapid progression of Fabry nephropathy. The eGFR pro-
gression rate may increase with advancing nephropathy,
and may differ between subgroups of patients with Fabry
disease.
Keywords: albuminuria; arrhythmia; Fabry disease; nephropathy;
proteinuria; stroke
Introduction
Fabry disease is an X-linked lysosomal storage disorder
due to alpha-galactosidase A (α-GalA) deficiency. This
deficiency causes the progressive accumulation of globo-
triaosylceramide (GL-3) and related glycosphingolipids,
particularly in vascular endothelial cells, renal cells and
cardiomyocytes [1].
Nephropathy is one of the major complications of Fabry
disease. Biopsies reveal GL-3 accumulation in tubular ep-
ithelial cells, glomerular and endothelial cells, with focal
and global glomerulosclerosis as early as in the second
decade of life [2–5]. The major signs of Fabry nephropa-
thy include reduced glomerular filtration rate (GFR), isos-
thenuria and proteinuria [1,3,6], and affected males typ-
ically progress to kidney failure by the fourth decade of
life [7]. Cardiovascular and cerebrovascular events also
contribute to morbidity and mortality. Heterozygous fe-
males may be asymptomatic or develop overt disease, pre-
sumably due to skewing of X-chromosomal inactivation
[1,8–12].
The natural history of Fabry disease in patients prior to
receiving enzyme replacement therapy (ERT) may provide
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insights to the underlying pathophysiology, and a context
for assessing outcomes once ERT is initiated. Therefore,
we conducted a chart review of 447 patients to document
the severity and progression of their nephropathy, as well as
cardiovascular and cerebrovascular events and death before
ERT.
Materials and methods
Study design
We obtained a collection of retrospective data from patients with Fabry
disease followed between 1944 (first record across all datasets) and 2002.
The clinical records of 447 patients from 27 participating expert sites in
five countries (USA 19 sites, Canada 5 sites and 1 site in Czech Republic,
Denmark and the Netherlands) were reviewed.
Once patients, guardians or next of kin consented and medical records’
release had been obtained after local Institutional Review Board ap-
proval, if applicable, all available pre-defined clinical data were abstracted
onto case report forms by an independent contract research organization
[Abt Associates Clinical Trials (AACT), Cambridge, MA, USA]. The ab-
stracted information included patient and disease characteristics, key lab-
oratory values over time and history of renal, cardiac and cerebral vascular
diseases. Patient names remained blinded. Duplicate patient data obtained
at more than one site were identified, and patients’ records were merged.
Statistical services were provided by Genzyme Corporation, Cambridge,
MA, USA.
Patients
Eligible patients included those diagnosed with Fabry disease during life
or at the time of death. Based on review of the clinical findings, α-GalA
activities and α-GalA genotypes, most (>95%) of the affected males and
heterozygous females had orwere from familieswith the classic phenotype
[1,13,14]. Patients were excluded if they had confounding renal or other
diseases (e.g. diabetic nephropathy, cancer). Charts were abstracted only
up to the time of initiation of ERT.
Data collection and analysis
Fabry nephropathy. Data collected included chronic renal insufficiency
or failure, and proteinuria or ratio of urinary protein to urinary cre-
atinine (>0.3 g protein per day or >0.3 g/g). End-stage renal dis-
ease (ESRD) was defined by a requirement for chronic dialysis or
transplantation. A renal event was defined as kidney transplantation,
>40 days of chronic dialysis, an increase in serum creatinine by 50%
from baseline (i.e. at first entry in the abstracted medical records) to a
value >1.4 mg/dl or serum creatinine ≥6 mg/dl.
Available serum creatinine values for 243 males and 152 fe-
males were used to calculate eGFR [15]. These patients were strat-
ified by their baseline eGFR ≥60 or <60 ml/min/1.73 m2. Chronic
kidney disease (CKD) staging was not used because the creati-
nine measurements were from multiple centres, but those with eGFR
<60 ml/min/1.73 m2 were classified as having CKD [15]. For blood
pressure, body weight, body mass index (BMI) and urinary protein,
the data recorded within ± 1 year and closest to the baseline eGFR
were used for computations. To be certain that the initial values ex-
tracted from the medical records were a valid representation of the
baseline status of the patients, repeated measures of weight, systolic
and diastolic blood pressures and urinary protein excretion within 6
months of the initial assessment showed no significant changes, ex-
cept for diastolic blood pressure for which there was a 3.9 mmHg de-
crease. The second assessment of eGFR did not occur until 2.6 years
after the initial assessment, and revealed a decline in kidney function of
−2.38 ml/min/1.73 m2/year, which is consistent with the overall decline
in eGFR reported in this paper. The median number of serum creatinine
determinations available for the patients was 6 (range 3–33) samples, and
the median follow-up period for the patients was 5.6 years (range 0.1–28.2
years). The median date for the initial creatinine assessment for the cohort
was July 1994 (range June 1963–September 2001). Patients with three or
more eGFR assessments were included in eGFR slope calculations; data
from patients after they had reached ESRD were excluded. The eGFR
slopes were computed for patients stratified by baseline eGFR ≥60 or
<60 ml/min/1.73 m2 (CKD), as well as by baseline urinary protein groups
(<0.1, 0.1 to <1 and ≥1 g/24 h).
Cardiac events. Events included myocardial infarction (MI) determined
by electrocardiographic (ECG) changes, probable ECG changewith symp-
toms and abnormal enzymes or MI noted in the medical records; per-
cutaneous transluminal coronary angioplasty; intra-aortic balloon pump;
coronary artery bypass graft; valve replacement; any type of arrhythmia
[i.e. bradyarrhythmias, ventricular arrhythmias, supraventricular arrhyth-
mias, premature (extra) beats] and presence of related symptoms, anti-
arrhythmic medication, cardioversion, pacemaker, defibrillator; angina
(new, rest or increasing angina, ECG with angina) and heart failure (phys-
ical findings, dyspnoea, imaging and intravenous medications).
Cerebrovascular events. These included stroke or transient ischaemic
attacks (TIA) classified by vascular territory or by amaurosis fugax. Stroke
was classified as due to haemorrhage or infarction, and the territory was
noted.
Other clinical data. These included demographics, α-GalA mutation,
onset of symptoms, weight, blood pressure, use of angiotensin-converting
enzyme (ACE) inhibitors and diabetes. The dates were recorded for first
symptom attributed to Fabry disease and for death.
Mutational analyses
Genomic DNA was isolated from blood collected in EDTA, and the α-
GalA exons and adjacent intronic and promoter regions were sequenced
using standard techniques [14,16].
Statistical analyses and calculations
Means with standard deviations and/or medians with ranges were used to
summarize continuous variables. Mixed models with random intercepts
and slopes for each patient, and fixed effects for gender and eGFR and
proteinuria subgroups were used for eGFR slopes. Baseline eGFR was
used as a covariate in the mixed models. Time to first renal, cardiac or
stroke event, or death was determined using Kaplan–Meier curves by
gender.
Results
Patient population
Characteristics of the 447 patients are presented in Table 1.
Themean age at first entry in the abstractedmedical records
(baseline) was 38.6 and 44.9 years for males and females,
respectively; data were available for a median of 12 years
per patient. Symptom onset for males was usually before
the age of 15 years (mean 10.5 years), whereas age at first
symptom was later for females (mean 17.4 years). Females
were also diagnosed later than males (mean age 29.7 ver-
sus 23.9 years, respectively). Patients with a known family
history had earlier diagnoses [24.8 ± 14.7 years (n = 352)
versus 34.2 ± 16.8 years (n = 52)]. The diagnosis of Fabry
disease was confirmed by α-GalA activity and/or mutation
analyses in 96% of the patients.
Fabry nephropathy
Estimated glomerular filtration rate. Baseline serum cre-
atinine values were obtained for 243 males and 152 fe-
males and used to calculate eGFR with the MDRD equa-
tion [15]. Table 2 presents patient characteristics stratified
by gender and baseline eGFR ranges. The average age of
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Table 1. Patient characteristics
Male (n = 279) Female (n = 168) Total (n = 447)
Mean (range) age, years
At data abstraction 38.6 (5.0–73.0) 44.9 (10.3–77.1) 41.0 (5.0–77.1)
At first symptom (n = 263, 185 M, 78 F) 10.5 (0.3–56.0) 17.4 (2.6–56.1) 12.6 (0.3–56.1)
At diagnosis (n = 404, 258 M, 146 F) 23.9 (0–66.5) 29.7 (0–76.2) 26.0 (0–76.2)
At death 49.9 (34.5–59.4) 52.6 (36.3–70.1) 50.3 (34.5–70.1)
Number of patients deceased, n (%) 20 (7) 3 (2) 23 (5)
Ethnicity, n (%)
White 238 (85) 144 (86) 382 (85)
Hispanic 20 (7) 5 (3) 25 (6)
African American 6 (2) 2 (1) 8 (2)
Asian 1 (0) 0 (0) 1 (0)
Not reported 10 (4) 16 (10) 26 (6)
Diagnostic confirmation, n (%)
α-GalA activity and mutation 212 (76) 128 (76) 340 (76)
α-GalA activity, only 29 (10) 18 (11) 47 (11)
α-GalA mutation, only 23 (8) 17 (10) 40 (9)
α-GalA activity/mutation not reporteda 15 (5) 5 (3) 20 (4)
α-GalA activity
Plasma (nmol/h/ml)
n 120 64 NA
Mean (±SD) 1.0 (1.85) 6.2 (6.11) NA
Leukocytes (nmol/h/mg)
n 121 82 NA
Mean (±SD) 2.1 (3.67) 28.3 (29.30) NA
Fabry genotypeb, n 238 145 383
Missense, n (%) 117 (49) 74 (51) 191 (50)
Nonsense, n (%) 49 (21) 29 (20) 78 (20)
Deletion, n (%) 42 (18) 22 (15) 64 (17)
Insertion, n (%) 9 (4) 4 (3) 13 (3)
Splice site, n (%) 10 (4) 7 (5) 17 (4)
Complex, n (%) 5 (2) 3 (2) 8 (2)
Residual activity variant, n (%) 6 (3) 6 (4) 12 (3)
NA, not applicable; SD, standard deviation; α-GalA, alpha-galactosidase A.
aOf the 20 patients with α-GalA activity/genotype not reported, 14 (11 males and 3 females) have reported a family history of Fabry disease and 3
others had α-GalA activity values, but the units were not specified.
bPercentages are based on the number of patients with genotype data in each column.
Table 2. Clinical values in Fabry males and females stratified by baseline estimated glomerular filtration rate (eGFR; ml/min/1.73 m2)
Males Females
eGFR ≥60 (n = 189) eGFR <60a (n = 54) eGFR ≥60 (n = 129) eGFR <60a (n = 23)
Age at baseline eGFR
Mean (SD) 27.3 (11.9) 41.8 (9.9) 38.0 (14.0) 51.9 (12.3)
Urinary protein (g/24 h), n 52 25 40 8
Mean (SD) 0.6 (1.0) 2.6 (2.3) 0.3 (0.4) 1.1 (1.5)
Median 0.2 1.7 0.2 0.3
Range 0–5.7 0.3–8.7 0–1.7 0–4.3
Overt proteinuriab, n (%) 19 (37) 24 (96) 8 (20) 4 (50)
ACE inhibitor use, n (%) 26 (14) 22 (41) 13 (10) 5 (22)
Blood pressurec, n 151 46 98 15
Systolic, mean (SD) 125 (15) 128 (17) 123 (18) 135 (18)
Diastolic, mean (SD) 74 (12) 79 (12) 75 (12) 82 (7)
Hypertensived, n (%) 98 (52) 43 (80) 62 (48) 18 (78)
SD, standard deviation; eGFR, estimated glomerular filtration rate.
.aCKD defined as eGFR <60 ml/min/1.73 m2.
bOvert proteinuria defined as >0.3 g protein in 24-h urine collection. Urinary protein assessment is the closest available reading within ± 1 year of
baseline eGFR assessment.
cBlood pressures are the closest reading within ± 1 year of baseline eGFR assessment.
dHypertension is defined as systolic ≥130 or diastolic ≥80 mmHg, or patient is indicated on case report form as hypertensive on medications.
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Fig. 1. eGFR regression slopes with 95% CI for male and female patients
who progressed to ESRD during the observation period, compared to those
who did not progress to ESRD, based onmedical record review. ESRDwas
defined by institution of renal replacement therapy (dialysis or transplant)
or achieving a serum creatinine >6 mg/dl. The eGFR (ml/min/1.73 m2)
and progression rates (ml/min/1.73 m2/year) were averaged for all patients
who had at least three serum creatinine determinations available from the
medical record review. Modelling lines for patients who progressed to
ESRDwere extended back to start at the minimum age for baseline eGFR,
i.e. ∼20 years for males and ∼30 years for females (see Table 5). The
lines end on average at about the age of ESRD for these patients, i.e. ∼40
years. Modelling lines for patients without ESRD were extended to cover
the ages where the data ended, i.e. ∼70 years for some females and ∼60
years for some males.
males with baseline eGFR ≥60 (n = 189) or CKD [eGFR
<60 ml/min/1.73 m2 (n= 54)] was 27.3 and 41.8 years, re-
spectively. A similar pattern was seen in females although
the baseline eGFR values were obtained about 10 years
later: 38.0 (n = 129) and 51.9 (n = 23) years, respectively.
Urinary protein values were available for 125 (32%) pa-
tients at the time that their baseline serum creatinine values
were recorded. Overt proteinuria (>0.3 g/24 h) was present
in 96% of males and 50% of females with baseline CKD.
Patients with CKDmore commonly received ACE inhibitor
therapy, but only aminority ofmales and females with CKD
were treated with these drugs.
Hypertension. The mean systolic and diastolic blood
pressures were normal: 124 mmHg (range 70–186) systolic
and 71 mmHg (range 42–111) for 142 males ≤30 years of
age, and 119 mmHg (range 90–172) systolic and 72 mmHg
(range 43–110) for 50 females ≤30 years of age; and
130 mmHg (range 86–174) systolic and 76 mmHg (range
43–110) for 188 males >30 years of age, and 127 mmHg
(range 85–185) systolic and 77 mmHg (range 49–110) for
126 females >30 years of age. Hypertension (systolic or
diastolic blood pressure>130 or>90 mmHg, respectively)
was present in 14% of 142 and 27% of 188 males, and
6% of 50 and 22% of 126 females ≤30 and >30 years,
respectively. While ∼80% of both males and females with
CKD at baseline were hypertensive, only ∼50% of those
with baseline eGFR≥60ml/min/1.73m2 were hypertensive
(Table 2).
Progression of chronic kidney disease. The rate of eGFR
decline (progression) was stratified by gender and ultimate
progression to ESRD (Figure 1). Of males who had at least
three serum creatinine determinations, mean progression
rates for those who developed (n = 17) or did not de-
velop ESRD (n = 128) were −3.85 and −2.93 ml/min/
1.73 m2/year, respectively (difference statistically signifi-
cant, P = 0.0354). For females who developed (n = 4) or
did not develop ESRD (n = 51), mean progression rates
were −3.05 and −1.02 ml/min/1.73 m2/year, respectively
(P = 0.0653). When stratified by the CKD status (Table 3),
the progression rates were 2-fold greater for both males
and females who had baseline CKD compared to those who
had higher baseline eGFR values. The progression rates for
males with eGFR≥60ml/min/1.73m2 and CKDwere−3.0
and −6.8 ml/min/1.73 m2/year, respectively. Progression
rates for females with baseline eGFR ≥60 ml/min/1.73 m2
andCKDwere−0.9 and−2.1ml/min/1.73m2/year, respec-
tively. These progression rates were significantly higher for
males than for females in each baseline eGFR strata; P-
values were 0.043 and 0.037, respectively (Table 3). The
baseline ages for each group, as well as the duration of
follow-up after the baseline, are also shown in Table 3.
Progression rates were stratified by baseline urinary pro-
tein excretion (Figure 2). Higher baseline proteinuria levels
were associated with more rapid progression rates. The
rates were −1.6, −3.3 and −6.9 ml/min/1.73 m2/year in
males with baseline proteinuria <0.1 g/24 h, 0.1–1 g/24 h
and ≥1 g/24 h, respectively (Table 4). A similar finding
was seen in females stratified for baseline proteinuria: the
rates were −0.66, −2.2 and −4.6 ml/min/1.73 m2/year in
females with baseline proteinuria <0.1 g/24 h, 0.1–1 g/
24 h and ≥1 g/24 h, respectively (Table 4). Males and fe-
males with higher baseline levels of proteinuria were older
and had lower baseline eGFR values; they also had greater
progression rates than those with less proteinuria (Table 4).
End-stage renal disease. A total of 49males and 8 females
progressed to ESRD, at amedian age of 39.5 and 42.4 years,
respectively (Table 5). They had advanced Fabry nephropa-
thy at the baseline evaluation, with average eGFR for males
(n = 32) and females (n = 6) of 40.9 and 22.3 ml/min/
1.73m2, respectively. Themean ages at baseline evaluations
were 37.8 (males) and 42.0 years (females). For those with
documented proteinuria, 90% of males and all females who
progressed to ESRD had overt proteinuria (>0.3 g/24 h).
Average values were 3.0 ± 2.7 g/24 h for males and 2.1 ±
2.0 g/24 h for females (Table 5). Fifty-seven patients
reached ESRD, and of these, 28 males and 5 females had
kidney transplants.
Cardiac and cerebrovascular events
There was an age difference between males and females at
the time of the first renal, cardiac or stroke event or death
(Figure 3A). The initial events occurred in males before
10 years of age and continued for decades. Females did not
have events until after 20 years of age. Half of the males
and females had an event by 41 and 53 years, respectively.
Cardiac events and interventions are summarized in
Table 6; 137 males (49%) and 59 (35%) females had an
event by a mean age of 36.2 and 44.4 years, respectively.
Forty-six patients (11% of males, 9% of females) with
available data were reported to have definite ECG changes.
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Table 3. Progression rates for males and females stratified by baseline estimated glomerular filtration rate (eGFR; ml/min/1.73 m2)
Males Females
Parameter eGFR ≥60 (n = 117) eGFR <60a (n = 28) eGFR ≥60 (n = 42) eGFR <60a (n = 13)
eGFR slope (ml/min/1.73 m2/year)b
Mean (SEM) −3.0 (0.1) −6.8 (1.5) −0.9 (0.9) −2.1 (1.6)
Time from baseline eGFR to last eGFR (years)
Mean (SD) 8.5 (6.8) 2.4 (2.5) 7.8 (7.2) 4.3 (2.5)
Median 6.7 1.3 5.6 4.4
Baseline age (years)
Mean (SD) 27.8 (12.0) 41.9 (10.5) 38.7 (13.1) 52.1 (13.6)
Median 27.0 42.0 38.7 50.7
SEM, standard error of the mean; SD, standard deviation; eGFR, estimated glomerular filtration rate.
P-values for differences males versus females; eGFR ≥60: P = 0.043; eGFR<60: P = 0.037. eGFR assessments after the start of dialysis or transplant
or serum creatinine>6 mg/dl (530 µmol/l) are not used in computation of eGFR slopes. Based on a mixed model with fixed effects for intercept, slopes
and covariate adjustment for baseline eGFR values along with random effects for individual patient intercepts and slopes.
aCKD defined as eGFR <60 ml/min/1.73 m2.
bPatients with three or more eGFR assessments were included in the eGFR slope calculations.
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Fig. 2. eGFR progression slopes (ml/min/1.73 m2/year) for male and female patients stratified by baseline 24-h urinary protein excretion (g/24 h). The
y-axis represents eGFR (ml/min/1.73 m2) and the x-axis in each panel represents a 12-month span. SEM = standard error of the mean.
Table 4. Characteristics of Fabry males and females stratified by baseline urinary protein
Males Females
Baseline proteinuria (g/24 h) <0.1 0.1–1.0 >1.0 <0.1 0.1–1.0 >1.0
Number of patients 18 21 22 7 17 5
Mean age, years (SD) 22.8 (12.8) 36.0 (12.1) 38.9 (10.3) 39.0 (22.0) 42.3 (12.1) 47.2 (11.7)
Progression rate, ml/min/1.73 m2/year (SEM) −1.6 (1.5) −3.3 (1.8) −6.9 (1.5) −0.6 (2.6) −2.2 (2.2) −4.6 (2.3)
Mean baseline eGFR, ml/min/1.73 m2 (SD) 138 (56.5) 84.6 (37.1) 58.5 (25.6) 91.9 (41.2) 89.6 (38.5) 63.4 (18.9)
Mean follow-up time, years (SD) 5.2 (5.4) 2.5 (3.0) 2.4 (2.1) 3.3 (2.0) 1.7 (1.6) 5.6 (1.6)
SD, standard deviation; SEM, standard error of the mean; eGFR, estimated glomerular filtration rate.
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Table 5. Summary information for patients with Fabry nephropathy who
developed end-stage renal diseasea
Males Females
ESRD patients (n) 49 8
Age at ESRD (years)
Mean (SD) 39.5 (9.6) 42.4 (11.7)
Median 39.5 41.3
Range 18.0–58.0 29.5–65.9
Baseline eGFR (ml/min/1.73 m2), n 32 6
Mean (SD) 40.9 (30.8) 22.3 (22.8)
Median 34.1 12.9
Range 38–110 1.5–53.5
Age at baseline eGFR (years)
Mean (SD) 37.8 (8.9) 42.0 (11.3)
Median 39.6 41.9
Range 19.9–52.6 29.5–61.7
Urinary proteinb (g/24 h), n 10 3
Mean (SD) 3.0 (2.7) 2.1 (2.0)
Median 2.3 1.4
Range 0.1–8.7 0.5–4.3
Overt proteinuriac, n (%) 9 (90) 3 (100)
Age at baseline urinary protein
(years)
Mean (SD) 34.3 (10.0) 46.2 (14.5)
Median 32.6 43.2
Range 19.9–48.8 33.4–61.9
Genotypes
Patients with genotypesd, n 36 5
Missense, n (%) 19 (52.8) 3 (60.0)
Non-sense, n (%) 8 (22.2) 1 (20.0)
Splicing defect, n (%) 3 (8.3) 1 (20.0)
Complex, deletion, insertion, or
frameshift, n (%)
6 (16.7) 0
SD, standard deviation; eGFR, estimated glomerural filtration rate; ESRD,
end-stage renal disease.
aSerum creatinine≥6 mg/dl (530µmol/l) or chronic dialysis or transplan-
tation.
bUrinary protein assessment is the closest reading within ± 1 year of
baseline eGFR assessment.
cOvert proteinuria defined as >0.3 g protein in 24-h urine collection.
dOf the 16 patients without genotypes, 3 males had leukocyte α-GalA
activity of 2, 7 and 16.4 nmol/h/mg, 2 (1 male and 1 female, respectively)
had plasma α-GalA activity of 0.47 and 3.8 nmol/h/ml, and 8 other patients
(7 males and 1 female) had reported a family history of Fabry disease.
Table 6. Summary of cardiac events in Fabry males and females
Males Females All patients
Cardiac event (n = 279) (n = 168) (n = 447)
Any cardiac event, n (%) 137 (49) 59 (35) 196 (44)
MI, n (%) 7 (3) 3 (2) 10 (2)
Definite ECG change,
n (%)
31 (11) 15 (9) 46 (10)
Probable ECG change
with symptoms and
abnormal enzymes,
n (%)
0 0 0
Death from MI, n (%) 0 0 0
Cardiac procedures, n (%) 20 (7) 9 (5) 29 (6)
PTCA 6 (2) 2 (1) 8 (2)
IABP 1 (0) 0 1 (0)
CABG 5 (2) 1 (1) 6 (1)
Valve replacement 3 (1) 0 3 (1)
Cardiac hospitalization 15 (5) 11 (7) 26 (6)
Angina, n (%) 37 (13) 23 (14) 60 (13)
Rest 12 (4) 10 (6) 22 (5)
Increasing 13 (5) 10 (6) 23 (5)
Change in resting ECG 3 (1) 3 (2) 6 (1)
New onset 15 (5) 16 (10) 31 (7)
Positive stress test 15 (5) 7 (4) 22 (5)
Cardiac failure, n (%) 11 (4) 2 (1) 13 (3)
Physical findings 7 (3) 1 (1) 8 (2)
Exercise intolerance 8 (3) 1 (1) 9 (2)
Cardiac imaging 8 (3) 1 (1) 9 (2)
IV medications 3 (1) 0 3 (1)
Arrhythmiaa, n (%) 116 (42) 46 (27) 162 (36)
Arrhythmia symptoms 27 (10) 21 (13) 48 (11)
Arrhythmia
interventions
Anti-arrhythmic
medication
3 (1) 4 (2) 7 (2)
DC-cardioversion 6 (2) 2 (1) 8 (2)
Pacemaker 9 (3) 1 (1) 10 (2)
Defibrillator 1 (0) 1 (1) 2 (0)
MI, myocardial infarction; PTCA, percutaneous transluminal coronary
angioplasty; IABP, intra-aortic balloon pump; CABG, coronary artery
bypass graft.
aIncludes bradyarrhythmias, ventricular arrhythmias, supraventricular ar-
rhythmias, premature (extra) beats.
Fig. 3. (A) Kaplan–Meier estimate of time to first renal, cardiac, stroke event or death. Events were defined as detailed in the section ‘Data collection
and analysis’. (B) Kaplan–Meier estimate of time to first cardiac arrhythmia. Male and female patients are shown as separate lines in each panel.
Cardiac arrhythmias were defined as detailed in the section ‘Data collection and analysis’.
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Table 7. Cerebrovascular events in Fabry males and females
Males Females All patients
Cerebrovascular event (n = 279) (n = 168) (n = 447)
TIAs, n (%) 17 (6) 6 (4) 23 (5)
Mean age at first TIA
in years (SD)
40.9 (13.2) 43.1 (15.5) 41.5 (13.5)
Strokes 30 (11) 14 (8) 44 (10)
Ischaemia 26 (9) 14 (8) 40 (9)
Large vessel infarcts 6 (2) 5 (3) 11 (2)
Small vessel infarcts 13 (5) 6 (4) 19 (4)
Unknown 7 (3) 3 (2) 10 (2)
Haemorrhagic 3 (1) 1 (0.5) 4 (1)
Mean age at first stroke
in years (SD)
41.7 (12.2) 44.9 (14.0) 42.7 (12.7)
TIA, transient ischaemic attack; SD, standard deviation.
Angina was reported in 13% of males and 14% of females.
MIs were reported for 7 (3%) males and 3 (2%) females.
Only 3% of patients (11 males, 2 females) had findings of
cardiac failure. Arrhythmias [including bradyarrhythmias,
ventricular arrhythmias, supraventricular arrhythmias, pre-
mature (extra) beats] were by far the most common cardiac
event, and were reported for 116 (42%) of the males and
46 (27%) of females. Approximately 1/3 of patients with
an arrhythmia reported symptoms with a higher percentage
of females (46%) than males (23%). Kaplan–Meier esti-
mates of time to first arrhythmia are shown in Figure 3B. In
males, arrhythmias first appeared in adolescence whereas
in females they appeared in the early 20s. By the age of 45
years, 50% of males had a documented rhythm disturbance.
Cerebrovascular events (Table 7) included TIAs [17 (6%)
males, 6 (4%) females] and strokes [30 (11%) males, 14
(8%) females]. The mean age for first TIA was 40.9 and
43.1 years, for males and females, respectively.
Ischaemic stroke was considerably more common than
haemorrhagic stroke (9% of males, 8% of females versus
1% of males, 0.5% of females) and was more often char-
acterized as small vessel infarcts. Ischaemic stroke was
reported for 16 (6%) males and 6 (4%) females, and mid-
dle cerebral was the most common location identified. The
mean age for first strokes was 41.7 and 44.9 years, and
for large vessel strokes 33.6 and 45.0 years for males and
females, respectively.
Events in young males. Twelve males <18 years had car-
diac or cerebrovascular events, consisting of arrhythmias
in 11 and a stroke in 1 at age 6.7 years. One male with
arrhythmia documented at age 17.5 years had an episode of
angina 4 years later.
Death
The mean age at death of 20 males was 49.9 years
(Table 1). Three females died of unknown causes at the age
of 36, 51 and 71 years, respectively. Kaplan–Meier analysis
(Figure 4) showed that male Fabry patients had a 10% risk
of death by 50 years of age, and the likelihood of death
increased 5-fold to 50% by the age of 60 years.
Fig. 4. Kaplan–Meier-estimated survival rates for male Fabry patients
(n = 279).
Discussion
This study defines the natural history of the renal, cardiac
and cerebrovascular complications in patients with Fabry
disease before institution of ERT. Retrospective chart re-
views, for a median of 12 years for each patient, described
the progression of Fabry nephropathy, and the frequency
and nature of life-threatening complications.
Males developed symptoms and were diagnosed earlier
than females, and themajority of womenwere symptomatic
with moderate to severe manifestations of Fabry disease.
This may reflect an ascertainment bias inherent in the study
design, but recent studies evaluating larger cohorts of fe-
males [8–12] have found that they range fromasymptomatic
to as severe as males with Fabry disease. An important
cause of phenotypic variation in females is presumably due
to random X-inactivation [8,11,12].
Rapid progression of the Fabry nephropathy was more
prevalent among males than females, and older patients
were more likely to have severe Fabry nephropathy at their
first evaluation. Patients who developed ESRD had more
rapid rates of progression than those who did not develop
ESRD. Patients with advanced Fabry nephropathy (e.g.
CKD) progressed more rapidly than those with baseline
eGFR ≥60 ml/min/1.73 m2.
Branton et al. reported a mean progression rate of
−12.2 ml/min/year in 14 untreated male Fabry patients
who had stage 3 CKD at baseline and progressed to ESRD
[17]. The progression rates ranged from −3.3 to −33.7 ml/
min/year, suggesting heterogeneity of the underlying
processes. Progression may accelerate as nephropathy
progresses, as the kidney function drops below a certain
threshold. The progression rate should be monitored as an
important outcome measure in Fabry nephropathy.
Overt proteinuria was an important finding in our study,
and in a recent Fabry Registry study [10], and was more
prominent in males and females with CKD. Overt protein-
uria was noted in 90% of males and all females who pro-
gressed to ESRD. Consistent with recent studies [18–22],
proteinuria was a risk factor for progression of nephropa-
thy. Females had a similar association between baseline
proteinuria and progression, but the slopes were less steep
than those in males with similar levels of proteinuria.
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Studies with ACE inhibitors showed that in type 1 dia-
betic [23] and nondiabetic patients with proteinuric CKD
[24,25], reduction of proteinuria was associated with slow-
ing of progression and lower risk of ESRD. Similar findings
have been obtainedwith type 2 diabetic patients treatedwith
angiotensin receptor blockers [26,27]. Data from the Fabry
patients in this study were mostly from the era before the
frequent use of these agents; only about a third of patients
with CKD received anti-proteinuric agents.
The progression rate of Fabry nephropathy for females
with eGFR values ≥60 ml/min/1.73 m2 was −0.9 ml/
min/1.73 m2/year, similar to that of healthy women. In con-
trast, females with CKD progressed more rapidly (−2.1 ml/
min/1.73 m2/year). When stratified by baseline proteinuria,
females with overt proteinuria had substantial progression
rates. These results show that proteinuria significantly in-
creases the rate of progression of Fabry nephropathy in
females.
Placebo-controlled clinical trials and open-label exten-
sion studies in patients with Fabry disease have evaluated
the effects of ERT with recombinant agalsidase alfa at
0.2 mg/kg every other week (EOW) [22,28] and agalsi-
dase beta at 1.0 mg/kg EOW [18,20,29]. ERT stabilizes
GFR in patients with early Fabry nephropathy (relatively
normal GFR, minimal proteinuria) [20,22] and clears GL-3
from renal cells [4]. Moreover, slowing of disease progres-
sion also has been shown for patients with moderate renal
disease [18,21]. Early diagnosis, comprehensive evaluation
of kidney function, aggressive management of the protein-
uria and early initiation of ERT should optimize efforts
to prevent or slow the progression of Fabry nephropathy
[18,20–22,30].
The present study confirms the high prevalence of car-
diac events [8,12,31], particularly of arrhythmias in Fabry
patients. Only 2% of the patients had MIs while 13% had
angina events. Comparison with non-matched data from
the general adult US population (MIs, 5.5% of males, 3.4%
of females; angina/coronary heart disease, 5.5% of males,
3.4% of females) [32] suggests that angina events may oc-
cur more frequently in Fabry patients. While no paediatric
females had a known arrhythmia event, arrhythmias were
relatively common amongmales aged<18 years. Thus, car-
diac evaluation should be routinely performed in teenage
and older Fabry patients [33].
The prevalence of TIAs and strokes was similar to other
reports [8,31]. Most strokes were ischaemic, and most were
small vessel infarcts. The most common documented loca-
tion was the middle cerebral distribution. Cardiac compli-
cations and hypertension, associated with CKD, are likely
contributing factors in the aetiology of TIAs and stroke in
Fabry patients [34]. The ages at which males and females
experienced cardiac events or strokes differed. On average,
females had these events in their third or later decades of
life, while males experienced them as early as in adoles-
cence. Hypertension was more prevalent in males than in
females. Whether hypertension is a risk factor for the oc-
currence of TIAs and stroke remains to be determined.
The mean age at death of 49.9 years for male patients
was similar to that reported by others [17], and represents
a reduction of approximately 25 years compared to the US
general population [35]. For female patients, a median cu-
mulative survival of 70 years has been previously reported
approximating a reduction of 10 years as compared to the
general population [35,36]. Early recognition of childhood
symptoms [37,38], and timely therapeutic intervention of-
fer the best hope for Fabry patients.
Although this study was carefully conducted with pre-
defined analysis of the medical records of patients seen at
expert centres, there are several evident limitations to this
study that have to be acknowledged: (a) incomplete, in-
consistent or erroneous documentation would decrease the
power of subgroup analyses; (b) the fact that data were ex-
tracted from primary medical records over a 60-year span
raises questions about validity and choice of endpoints.
There have been changes in laboratory methods for mea-
suring serum creatinine, and a central laboratory was not
used for uniform analyses. Renal events were defined as an
increase in measured serum creatinine by 50% to a value
>1.4mg/dl. Reference values have decreased over the years
by 0.2–0.4 mg/dl, so the absolute change in kidney function
cannot be over-interpreted other than to say that the 50%
change in measured creatinine was an indication of signif-
icant decline in function; (c) similar concerns can be raised
about using the extracted serum data to calculate eGFR pre-
cluding more detailed analysis of the eGFR data other than
the dichotomous distinction between CKD (eGFR <60)
and eGFR ≥60 ml/min/1.73 m2. However, the source of
variability is lessened by using the regression slopes of the
change in eGFR over time; (d) despite the fairly robust size
of the cohort, the numbers of patients in some categories
(e.g. the patients who progressed to ESRD in Figure 1) is
too small to make meaningful comparisons between the
categories; (e) a number of symptomatic complaints [e.g.
premature (extra) beats]were retrospectively extracted from
the medical records; (f) selection bias may well have influ-
enced the inclusion of more severely affected individuals,
and could have delayed the inclusion of female patients
who were previously thought to be ‘carriers’ without im-
portant manifestations of Fabry disease and (g) the possi-
bility that the regression slope of change in MDRD eGFR
with time may underestimate the true rate of progressive
loss of kidney function, especially if the GFR is relatively
normal, is well described [39]. As a consequence, Fabry
patients with low-grade proteinuria and relatively normal
GFR, such as those presented in Figure 2, may have greater
rates of progression than would be estimated by the current
methodology.
Within these considerations, this study extends the ex-
isting knowledge of the natural history of Fabry disease
prior to the initiation of ERT and, in particular, describes
the progression rates of the Fabry nephropathy for patients
stratified by gender and baseline proteinuria.
In conclusion, male patients with Fabry disease typically
progressed more rapidly than females, but a considerable
number of female patients in fact do have progressive Fabry
nephropathy. Higher baseline proteinuria, systemic hyper-
tension and lower baseline eGFR were associated with pro-
gression of eGFR loss and are important in evaluating thera-
peutic expectations and the response to ERT and adjunctive
therapies in Fabry disease.
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Abstract
Background. Microalbuminuria (MA) is a known predic-
tor of cardiovascular disease (CVD) in European origin
populations, but such data are lacking in native Indo-Asian
populations, where CVD risks are high. Major electrocar-
diographic (ECG) changes are predictive of cardiovascular
mortality.We determined the association ofMAwith major
ECG changes in the general population of Pakistan.
Methods. A total of 3143 subjects aged ≥40 years from
12 randomly selected communities in Karachi participated.
MA was defined as the urine albumin to creatinine (ACR)
ratio of < 300 mg/g creatinine and ≥17 mg/g in men and
≥25mg/g in women from a single-spot morning urine sam-
ple. Major changes on ECG were coded in duplicate using
Minnesota classification.
Results. The mean age of subjects was 51.5 (10.7) years.
The median (25–75 percentile) ACR was 4.2 (2.9–7.9)
mg/g in men and 6.0 (3.9–10.8) mg/g in women (P <
0.001). The overall prevalence (95% CI) of MA was 12.3%
(11.1–13.5%), and 20.3% in those with major ECG
changes. In a multivariable model, major ECG changes
(OR, 95%CI) (1.50, 1.10–2.00), diabetes (3.57, 2.93–4.35),
hypertension (2.30, 1.85–2.86), female sex (0.61, 0.53–
0.69), age (1.09, 1.05–1.13, for each 5-year increase) and
eGFR (0.80, 0.78–0.81, for each 10 mg/g increase) were
independently associated with MA.
The presence of MA increased the prevalence of ma-
jor ECG changes from 21 to 31% in those with hyper-
tension (44.9%), 15 to 28% among those with diabetes
(21.4%), 14 to 26% among those with overweight or obe-
sity (68.4%) and 14 to 26% among current users of tobacco
(38.7%) (P < 0.001) each.
Conclusions. The strong association between MA and ma-
jor ECG changes underscores the importance of screen-
ing Indo-Asian subjects for MA for unmasking underlying
CVD, especially those with hypertension, diabetes, obesity,
and tobacco users.
Keywords: cardiovascular disease; ethnicity; hypertension;
microalbuminuria
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